Intra-cellular Therapies, Inc.

Microsoft Technology Licensing, LLC

Jun Zhao

Peng Li

Lawrence P Wennogle

Hailin Zheng

Hailin Zeng

Eric C Young

Timothy Jesse Tien

Edward Un

Zongyi Liu

Devesh Mishra

Kai Wang

Hua Li

Zeyong Xu

Hailong Mu

Sameer Vinod Shah

John Ian Ferrell

Zhifeng Wang

Kaiyan Tian

Mattias Beermann

Edward Ding-Bong Un

The present invention relates to PDEI inhibitory compounds of Formula I as described herein, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.

Organic compounds

The present invention relates to novel pyridinoxy phenylpropanamines, their pharmaceutical compositions and methods of use. In addition, the present invention relates to therapeutic methods that penetrate the blood-brain barrier and regulate the norepinephrine and serotonin transporters ('NET/SERT').

The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.

Compounds and methods

The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), according to Formula I, below, wherein R, R, Rand Rare as defined herein, useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

Optionally substituted (1- or 3-oxy)-4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or (1- or 3-oxy)-4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.

PDE1 inhibitory compounds and methods

Among other things, one or more techniques and/or systems are provided for locating a position within an enclosure. In one example, known global coordinates (e.g., GPS coordinates of latitude/longitude) associated with the position within the enclosure may be transformed into local coordinates (e.g., x/y coordinates) for the position. The local coordinates may be used for tracking a location of the position within the enclosure. In another example, known local coordinates of the position within the enclosure may be transformed into global coordinates for the position, which may be used for tracking a location of the position within the enclosure. In another example, a blueprint image of the enclosure may be used to track a location of the position within the enclosure. In this way, location tracking may be provided for objects within indoor spaces (e.g., a mapping application may track a current position of a mobile device within a building).

Locating position within enclosure

Techniques for utilizing APs and messaging service for delivering personalized message to individual mobile devices connected to internet through APs. In one example embodiment, for any particular wireless AP, a set of messages are identified based at least in part on attributes of the service subscriber associated with the particular wireless AP; and the set of messages are distributed to the particular wireless AP for further distribution to wireless devices in the vicinity of the particular wireless AP.

WiFi proximity messaging

Provided are PDE1 inhibitors of Formula I, processes for their production and their use as pharmaceuticals, and pharmaceutical compositions comprising them.

The present invention relates to optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidine compounds, and methods of using said compound, e.g., wherein the treatment relates to diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as, among others, Parkinson's disease, depression, narcolepsy, damage to cognitive function, e.g., in schizophrenia.

Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

Optionally substituted (5- or 7- amino)-3,4-dihydro-(optionally 4-oxo, 4-thioxo or 4-imino)- 1H-pyrrolo [3,4-d]pyrimidin-2(6H)-ones, Compounds of Formula I, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.

Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I

The present invention relates to (1- or 2- and/or 5 and/or 7-substituted)-(3-oxy)-(4H,4-imino, 4-thioxo or 4-oxo)-pyrazolo[3,4-d]pyrimidin-6-ones, e.g., a compound of formula II as described below, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. Of particular interest are novel compounds useful as inhibitors of phosphodiesterase 1 (PDE1), e.g., in the treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy, damage to cognitive function, e.g., in schizophrenia, or disorders that may be ameliorated through enhanced progesterone-signaling pathway, e.g., female sexual dysfunction.

Growing community of inventors

New York, NY, United States of America

Jun Zhao